EQT Group Life Sciences’ BioCapital Europe in Amsterdam

We’re looking forward to attending EQT Group Life Sciences’ BioCapital Europe in Amsterdam next week, alongside investors, partners, and fellow innovators shaping the future of life sciences.

Our CEO, Jan Thirkettle, will take the stage on Wednesday 4 March at 11:20am CET, presenting the Harness Therapeutics story. He’ll share how our proprietary MISBA® platform is unlocking previously undruggable targets in neurodegenerative diseases and how our lead candidate, HRN001, is advancing a differentiated, first-in-class approach for Huntington’s disease.

hashtag#BioCapital hashtag#HarnessTherapeutics hashtag#MISBA hashtag#HRN001 hashtag#HuntingtonsDisease hashtag#NeurodegenerativeDiseases

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

View all